Company / Shareholders' Equity
Akebia Therapeutics, Inc. Shareholders' Equity History
FY2014-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Shareholders' Equity
$32.6M
FY2025
5-year range
-$49.2M / $394.8M
FY2021-FY2025
Trend
+166.3%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Shareholders' Equity returned to growth in FY2025 after 4 years of decline, reaching $33M.
Based on SEC 10-K filings.
$33M in FY2025 with a 5-year CAGR of -44.8%.
Improved from -$31M to $33M over the past 2 years.
Shareholders' Equity over time
Growth rates
- 3-Year CAGR
- +84.1%
- 5-Year CAGR
- -44.8%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of -44.8%, indicating a declining trend.
- In FY2025, shareholders' equity increased 166.3% year-over-year.
- Peak shareholders' equity was recorded in FY2020.
- Lowest shareholders' equity in the period was in FY2015.
Company context
Key Data Points
- Altman Z-Score -2.76 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Shareholders' EquityValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $32.6M | +166.3% |
| FY2024 | -$49.2M | -60.8% |
| FY2023 | -$30.6M | -684.8% |
| FY2022 | $5.2M | -98.7% |
| FY2021 | $394.8M | -37.9% |
| FY2020 | $635.9M | +418.8% |
| FY2019 | $122.6M | +79.9% |
| FY2018 | $68.1M | +153.6% |
| FY2015 | -$127.1M | -113.3% |
| FY2014 | -$59.6M | - |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026